ambroxol has been researched along with Idiopathic Parkinson Disease in 16 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ambroxol therapy was well tolerated, with no serious adverse events." | 6.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
| "Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 6.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
| "Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 6.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
| "Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 5.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
| "Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 5.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
| "Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 5.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
| " The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher disease and Parkinson’s disease associated with GBA variants has been reviewed." | 5.22 | Pharmacological chaperone therapy for the treatment of inborn errors of metabolism ( Jezela-Stanek, A; Lipiński, P; Tylki-Szymańska, A, 2022) |
| "Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease α-synuclein and phosphorylated α-synuclein protein levels." | 3.83 | Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. ( Bezard, E; Daly, L; Migdalska-Richards, A; Schapira, AH, 2016) |
| "The ambroxol therapy was well tolerated, with no serious adverse events." | 2.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
| "Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 2.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
| "Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 2.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
| "Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 1.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
| "Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 1.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
| "Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 1.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, SY | 2 |
| Taanman, JW | 2 |
| Gegg, M | 2 |
| Schapira, AHV | 3 |
| Tripathi, P | 1 |
| Ganeshpurkar, A | 1 |
| Singh, SK | 1 |
| Krishnamurthy, S | 1 |
| Lipiński, P | 1 |
| Jezela-Stanek, A | 1 |
| Tylki-Szymańska, A | 1 |
| Mullin, S | 1 |
| Smith, L | 1 |
| Lee, K | 1 |
| D'Souza, G | 1 |
| Woodgate, P | 1 |
| Elflein, J | 1 |
| Hällqvist, J | 1 |
| Toffoli, M | 1 |
| Streeter, A | 1 |
| Hosking, J | 1 |
| Heywood, WE | 1 |
| Khengar, R | 1 |
| Campbell, P | 1 |
| Hehir, J | 1 |
| Cable, S | 1 |
| Mills, K | 1 |
| Zetterberg, H | 1 |
| Limousin, P | 1 |
| Libri, V | 1 |
| Foltynie, T | 2 |
| Schneider, SA | 1 |
| Alcalay, RN | 1 |
| Istaiti, M | 1 |
| Revel-Vilk, S | 1 |
| Becker-Cohen, M | 1 |
| Dinur, T | 2 |
| Ramaswami, U | 1 |
| Castillo-Garcia, D | 1 |
| Ceron-Rodriguez, M | 1 |
| Chan, A | 1 |
| Rodic, P | 1 |
| Tincheva, RS | 1 |
| Al-Hertani, W | 1 |
| Lee, BH | 1 |
| Yang, CF | 1 |
| Kiec-Wilk, B | 1 |
| Fiumara, A | 1 |
| Rubio, B | 1 |
| Zimran, A | 2 |
| Kopytova, AE | 1 |
| Rychkov, GN | 1 |
| Nikolaev, MA | 1 |
| Baydakova, GV | 1 |
| Cheblokov, AA | 1 |
| Senkevich, KA | 1 |
| Bogdanova, DA | 1 |
| Bolshakova, OI | 1 |
| Miliukhina, IV | 1 |
| Bezrukikh, VA | 1 |
| Salogub, GN | 1 |
| Sarantseva, SV | 1 |
| Usenko, TC | 1 |
| Zakharova, EY | 1 |
| Emelyanov, AK | 1 |
| Pchelina, SN | 1 |
| Silveira, CRA | 1 |
| MacKinley, J | 1 |
| Coleman, K | 1 |
| Li, Z | 1 |
| Finger, E | 1 |
| Bartha, R | 1 |
| Morrow, SA | 1 |
| Wells, J | 1 |
| Borrie, M | 1 |
| Tirona, RG | 1 |
| Rupar, CA | 1 |
| Zou, G | 1 |
| Hegele, RA | 1 |
| Mahuran, D | 1 |
| MacDonald, P | 1 |
| Jenkins, ME | 1 |
| Jog, M | 1 |
| Pasternak, SH | 1 |
| McNeill, A | 1 |
| Magalhaes, J | 1 |
| Shen, C | 1 |
| Chau, KY | 3 |
| Hughes, D | 1 |
| Mehta, A | 1 |
| Cooper, JM | 1 |
| Abramov, AY | 1 |
| Schapira, AH | 3 |
| Albin, RL | 1 |
| Dauer, WT | 1 |
| Ambrosi, G | 1 |
| Ghezzi, C | 1 |
| Zangaglia, R | 1 |
| Levandis, G | 1 |
| Pacchetti, C | 1 |
| Blandini, F | 1 |
| Maor, G | 1 |
| Cabasso, O | 1 |
| Krivoruk, O | 1 |
| Rodriguez, J | 1 |
| Steller, H | 1 |
| Segal, D | 1 |
| Horowitz, M | 1 |
| Sanchez-Martinez, A | 1 |
| Beavan, M | 2 |
| Gegg, ME | 1 |
| Whitworth, AJ | 1 |
| Migdalska-Richards, A | 1 |
| Daly, L | 1 |
| Bezard, E | 1 |
| Ishay, Y | 1 |
| Szer, J | 1 |
| Ilan, Y | 1 |
| Arkadir, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease[NCT02941822] | Phase 2 | 23 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial[NCT05287503] | Phase 2 | 65 participants (Actual) | Interventional | 2022-02-15 | Active, not recruiting | ||
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Genotypic Influences on Network Progression in Parkinson's Disease[NCT04228172] | 32 participants (Anticipated) | Observational | 2020-02-24 | Recruiting | |||
| Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy[NCT03950050] | Phase 2 | 40 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ambroxol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Pharmacological chaperone therapy for the treatment of inborn errors of metabolism
Topics: Ambroxol; Gaucher Disease; Humans; Mutation; Parkinson Disease | 2022 |
Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Drug Discovery; Expectorants; Gaucher Disease; Glucosyl | 2018 |
2 trials available for ambroxol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
12 other studies available for ambroxol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Topics: alpha-Synuclein; Ambroxol; Cathepsin D; Cells, Cultured; Cholinergic Agents; Glucosylceramidase; Hum | 2022 |
Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies.
Topics: Ambroxol; Animals; Catalytic Domain; Glucosylceramidase; Molecular Dynamics Simulation; Parkinson Di | 2022 |
Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
Topics: Ambroxol; Glucosylceramidase; Humans; Mutation; Parkinson Disease; Precision Medicine | 2020 |
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Topics: Adolescent; Adult; Aged; Ambroxol; Biological Availability; Blood-Brain Barrier; Child; Child, Presc | 2021 |
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Enzyme Inhibitors; Female; Gaucher Diseas | 2021 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Magic shotgun for Parkinson's disease?
Topics: alpha-Synuclein; Ambroxol; Female; Fibroblasts; Gaucher Disease; Glucosylceramidase; Humans; Male; M | 2014 |
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Topics: Aged; Ambroxol; Antiparkinson Agents; Cells, Cultured; Female; Fibroblasts; Glucosylceramidase; Huma | 2015 |
The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Topics: alpha-Synuclein; Ambroxol; Animals; Brain; Disease Models, Animal; Expectorants; Gaucher Disease; Gl | 2016 |
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Topics: Adipose Tissue; alpha-Synuclein; Ambroxol; Animals; Autophagy; Cell Differentiation; Dopaminergic Ne | 2017 |